XLMM
2022-01-04
Have been buying the dips!
Some Investors Should Buy Novavax Stock on the Dip
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":695028072,"tweetId":"695028072","gmtCreate":1641273866277,"gmtModify":1641274312612,"author":{"id":4100909250192760,"idStr":"4100909250192760","authorId":4100909250192760,"authorIdStr":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Have been buying the dips!</p></body></html>","htmlText":"<html><head></head><body><p>Have been buying the dips!</p></body></html>","text":"Have been buying the dips!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/695028072","repostId":1194204182,"repostType":2,"repost":{"id":"1194204182","kind":"news","pubTimestamp":1641264319,"share":"https://www.laohu8.com/m/news/1194204182?lang=&edition=full","pubTime":"2022-01-04 10:45","market":"us","language":"en","title":"Some Investors Should Buy Novavax Stock on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=1194204182","media":"InvestorPlace","summary":"The medium-term outlook of NVAX stock remains positive","content":"<html><head></head><body><p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) still remains poised to sell its vaccine for the coronavirus to many countries around the world, likely enabling it to generate very strong revenue in 2022 and possibly into 2023. Yet NVAX stock has fallen sharply in recent days.</p><p>That makes the shares very attractive for medium-term investors. Shares tumbled 25% in December alone.</p><p>On the positive side for Novavax and NVAX stock, on Dec. 20, a European MedicinesAgency (EMA) panel recommended that Novavax be able to market its vaccine for the coronavirus to adults in the EU.</p><p>As a result of this news, the EMA, the EU’s version of the Food and Drug Administration, is very likely to approve Novavax’s coronavirus vaccine for adults. And since the EU has agreed to purchase up to 200 million doses of Novavax’s vaccine, the approval is likely to lead to significant revenue for the company. And those sales, in turn, will probably lift NVAX stock in the medium term.</p><p>What’s more, after the EMA’s approval, I think that the FDA is much more likely than not to approve Novavax’s vaccine for three reasons. First, the EMA’s approval does indicate that the vaccine is safe and effective against the coronavirus.</p><p>Secondly, after the U.S. effectively discouraged the use of <b>Johnson & Johnson’s</b>(NYSE:<b><u>JNJ</u></b>) vaccine because of a side effect, I believe that Washington will want to have a shot that can appeal to those Americans who are nervous about the mRNA vaccines made by <b>Pfizer</b>(NYSE:<b><u>PFE</u></b>) and <b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>). It is, after all, true that the mRNA shots are based on relatively new technology and that Novavax’s vaccine is based on older, more conventional methods.</p><p>“The Novavax vaccine has no genetic material, only proteins,” Dr. Diana Florescu, who oversaw the Phase 3 trial of the shot,said in June, according to<i>Nebraska Medicine</i>. “The vaccine technology is more traditional, and it’s very similar to a protein-based influenza vaccine.”</p><p>Moreover, the U.S. has funded Novavax in the past and has agreed to purchase 100 million doses from it.</p><p>On a separate note, the World Health Organization approved Novavax’s shot on Dec. 17, opening the door for many more developing nations to purchase the vaccine.</p><p><b>The Mildness of Omicron Will Likely Reduce Demand for Novavax’s Jab</b></p><p>On the other hand, the relative mildness of the Omicron variation of Covid-19 is likely to, over the longer run, significantly lower the demand for Novavax’s shot. As evidence of that mildness, consider that a U.K.-based study recently found that those “with the omicron variant are 70% less likely to be hospitalized than those infected with the delta variant,<i>Seeking Alpha</i>reported.</p><p>The relative mildness could very well lower demand for Novavax’s vaccine in many countries. Still, I think there will still be meaningful demand in many nations. After all, many individuals, particularly those who are older and/or have more vulnerable immune systems, get flu shots every year.</p><p>And among most people, the fear of the coronavirus will likely always be stronger than the fear of the flu, even if there is little or no difference in their risk from the two illnesses. Consequently, I think that there will still be some demand for Novavax’s vaccine, especially in the medium-term, even if omicron proves to be little more risky than the flu for many people.</p><p><b>The Bottom Line on NVAX Stock</b></p><p>In my opinion, many investors think that Novavax may not get FDA approval for its shot and/or could have difficulties manufacturing and distributing its vaccine.</p><p>But after the EMA approved the shot, I think there’s an 80% chance that the FDA will also give it a thumbs up. And as I pointed out in my previous column, the drug maker is partnering with the <b>Serum Institute of India</b> on the manufacturing of its Covid-19 vaccine. I believe that the odds are good that Novavax will find multiple other manufacturing and distribution partners.</p><p>So although the long-term performance of NVAX could be hindered by lower-than-expected demand for its shot, I continue to believe that the shares’ medium-term outlook is favorable, given the partnerships and approvals that the firm likely to obtain during that period.</p><p>As a result, I urge medium-term, risk-tolerant investors to buy a relatively small amount of the shares on their current weakness.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some Investors Should Buy Novavax Stock on the Dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome Investors Should Buy Novavax Stock on the Dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-04 10:45 GMT+8 <a href=https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax(NASDAQ:NVAX) still remains poised to sell its vaccine for the coronavirus to many countries around the world, likely enabling it to generate very strong revenue in 2022 and possibly into 2023....</p>\n\n<a href=\"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2022/01/some-investors-should-buy-nvax-stock-on-the-dip/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194204182","content_text":"Novavax(NASDAQ:NVAX) still remains poised to sell its vaccine for the coronavirus to many countries around the world, likely enabling it to generate very strong revenue in 2022 and possibly into 2023. Yet NVAX stock has fallen sharply in recent days.That makes the shares very attractive for medium-term investors. Shares tumbled 25% in December alone.On the positive side for Novavax and NVAX stock, on Dec. 20, a European MedicinesAgency (EMA) panel recommended that Novavax be able to market its vaccine for the coronavirus to adults in the EU.As a result of this news, the EMA, the EU’s version of the Food and Drug Administration, is very likely to approve Novavax’s coronavirus vaccine for adults. And since the EU has agreed to purchase up to 200 million doses of Novavax’s vaccine, the approval is likely to lead to significant revenue for the company. And those sales, in turn, will probably lift NVAX stock in the medium term.What’s more, after the EMA’s approval, I think that the FDA is much more likely than not to approve Novavax’s vaccine for three reasons. First, the EMA’s approval does indicate that the vaccine is safe and effective against the coronavirus.Secondly, after the U.S. effectively discouraged the use of Johnson & Johnson’s(NYSE:JNJ) vaccine because of a side effect, I believe that Washington will want to have a shot that can appeal to those Americans who are nervous about the mRNA vaccines made by Pfizer(NYSE:PFE) and Moderna(NASDAQ:MRNA). It is, after all, true that the mRNA shots are based on relatively new technology and that Novavax’s vaccine is based on older, more conventional methods.“The Novavax vaccine has no genetic material, only proteins,” Dr. Diana Florescu, who oversaw the Phase 3 trial of the shot,said in June, according toNebraska Medicine. “The vaccine technology is more traditional, and it’s very similar to a protein-based influenza vaccine.”Moreover, the U.S. has funded Novavax in the past and has agreed to purchase 100 million doses from it.On a separate note, the World Health Organization approved Novavax’s shot on Dec. 17, opening the door for many more developing nations to purchase the vaccine.The Mildness of Omicron Will Likely Reduce Demand for Novavax’s JabOn the other hand, the relative mildness of the Omicron variation of Covid-19 is likely to, over the longer run, significantly lower the demand for Novavax’s shot. As evidence of that mildness, consider that a U.K.-based study recently found that those “with the omicron variant are 70% less likely to be hospitalized than those infected with the delta variant,Seeking Alphareported.The relative mildness could very well lower demand for Novavax’s vaccine in many countries. Still, I think there will still be meaningful demand in many nations. After all, many individuals, particularly those who are older and/or have more vulnerable immune systems, get flu shots every year.And among most people, the fear of the coronavirus will likely always be stronger than the fear of the flu, even if there is little or no difference in their risk from the two illnesses. Consequently, I think that there will still be some demand for Novavax’s vaccine, especially in the medium-term, even if omicron proves to be little more risky than the flu for many people.The Bottom Line on NVAX StockIn my opinion, many investors think that Novavax may not get FDA approval for its shot and/or could have difficulties manufacturing and distributing its vaccine.But after the EMA approved the shot, I think there’s an 80% chance that the FDA will also give it a thumbs up. And as I pointed out in my previous column, the drug maker is partnering with the Serum Institute of India on the manufacturing of its Covid-19 vaccine. I believe that the odds are good that Novavax will find multiple other manufacturing and distribution partners.So although the long-term performance of NVAX could be hindered by lower-than-expected demand for its shot, I continue to believe that the shares’ medium-term outlook is favorable, given the partnerships and approvals that the firm likely to obtain during that period.As a result, I urge medium-term, risk-tolerant investors to buy a relatively small amount of the shares on their current weakness.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1288,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":22,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/695028072"}
精彩评论